Bain Capital Life Sciences Investors’s Research Alliance Corp. II Class A Common Stock RACB Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio RACB Stock Details RACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000,000	Closed	-$9.8M	–	36
2022 Q2	$9.8M	Hold	1,000,000	–	–	1.15%	19
2022 Q1	$9.76M	Hold	1,000,000	–	–	0.95%	20
2021 Q4	$9.77M	Hold	1,000,000	–	–	0.77%	24
2021 Q3	$9.85M	Hold	1,000,000	–	–	0.61%	24
2021 Q2	$10.1M	Hold	1,000,000	–	–	0.66%	23
2021 Q1	$10.3M	Buy	+1,000,000	New	+$10.2M	0.58%	24

Other funds holding RACB

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Bain Capital Life Sciences Investors's RACB Position: Q3 2022 in Review

Bain Capital Life Sciences Investors sold out of Research Alliance Corp. II Class A Common Stock (RACB) in Q3 2022, closing a stake of 1,000,000 shares — an estimated $9.8M sold.

Bain Capital Life Sciences Investors first reported a position in RACB in Q1 2021 and held it in 6 quarters. The position peaked at $10.3M in Q1 2021. 40 funds tracked by Wall St. Rank hold RACB as of Q3 2022.

Bain Capital Life Sciences Investors reported no remaining Research Alliance Corp. II Class A Common Stock position as of Q3 2022 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,000,000 Research Alliance Corp. II Class A Common Stock shares in Q3 2022, an estimated $9.8M.
Bain Capital Life Sciences Investors first reported a position in Research Alliance Corp. II Class A Common Stock in Q1 2021 and held it in 6 quarters.
Bain Capital Life Sciences Investors's Research Alliance Corp. II Class A Common Stock position peaked at $10.3M in Q1 2021.
40 funds tracked by Wall St. Rank held Research Alliance Corp. II Class A Common Stock as of Q3 2022.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2022, filed 14 Nov 2022.